This CME/CPD module is available for completion online via BMJ Learning (learning.bmj.com) by subscribers to the online version of DTB.
If you would like to add online access to your current subscription, please contact our Customer Services team on +44 (0)20 7383 6270 or email support@bmjgroup.com. As well as allowing you to complete CME/CPD modules online, an online subscription also gives you unlimited access to the entire DTB archive back to volume 1, issue 1. 
Question 2
Answer: e. There were more than 1,100 registered deaths with a primary cause of asthma in England and Wales in 2013. 
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Question 5
Two replicate 48 week, randomised controlled studies compared the effect of tiotropium 5µg daily with placebo as add-on therapy to maintenance asthma therapy of high-dose inhaled corticosteroid (median daily dose 800µg budesonide equivalent) and long-acting beta 2 agonist. Which one of the following statements regarding these studies is correct? a. Patients enrolled in the studies had a ≥5-year history of asthma and ≥1 exacerbation treated with systemic corticosteroids in the previous 24 months b. The primary end point included admission to hospital for worsening asthma c. At 24 weeks, the difference from placebo in mean change in trough FEV 1 from baseline was 88mL and 111mL
d. There was no difference in time to first severe exacerbation between tiotropium and placebo e. No drug-related cardiac events were reported in the group taking tiotropium
Question 4
Answer: c. Compared with placebo the differences in trough FEV 1 in each trial were 88mL (95% CI 27 to 149, p<0.01) and 111mL (95% CI 53 to 169, p<0.001).
